Teleflex

Teleflex, Inc. provides medical technology products which enables healthcare providers to improve patient outcomes and enhance patient and provider safety. The firm designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for common diagnostic and therapeutic procedures in critical care and surgical applications. It operates through the following business segments: Americas, EMEA (Europe, the Middle East and Africa), Asia (Asia Pacific) and OEM. The Americas segment engages in the sales of interventional urology products. The EMEA engages in the sales of urology products. The Asia segment designs, manufactures and distributes medical devices primarily used in critical care, surgical applications and cardiac care and generally serves hospitals and healthcare providers. The OEM segment designs, manufactures and supplies devices and instruments for other medical device manufacturers. The company was founded in 1943 and is headquartered in Wayne, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Teleflex reports Q4 growth amidst challenges, eyes revenue acceleration

Teleflex's Q4 performance showed resilience with revenue growth and strategic acquisitions. While facing challenges like supply chain disruptions and UroLift revenue decline, the company is focused on margin expansion and disciplined growth. Opportunities lie in revenue acceleration, international expansion, and leveraging high-growth product categories.

Teleflex reports robust Q1 earnings, eyes growth amid challenges

Teleflex's Q1 2023 results reflect strong performance and strategic focus on sustainable growth, supported by geographic revenue growth and product category contributions.
While facing challenges in specific product lines and supply chain issues, the company maintains a disciplined approach to deals and cost management.
Opportunities lie in revised revenue guidance, product performance, and market improvements, positioning Teleflex for continued success in 2023.

Teleflex reports revenue growth and strategic acquisitions drive future outlook

Teleflex revised its 2023 financial guidance with revenue growth of 5.5% to 6.25% and adjusted EPS of $13 to $13.60. Despite challenges in certain product segments, the company remains confident in achieving its Long Range Plan growth objectives. The focus on integrating acquisitions like Palette and leveraging high-growth products positions Teleflex for continued success.

Teleflex reports robust Q3 results, eyes growth amidst challenges

Teleflex's Q3 performance reflects revenue and EPS growth, driven by operational improvements.
Despite challenges from GLP-1 impact and tax rate increases, the company remains optimistic.
Opportunities lie in market expansion, M&A activities, and product uniqueness strategies.
Overall, Teleflex's strong financials and strategic initiatives position it for continued growth.

Teleflex reports solid 2023 performance, eyes growth in Urology market

Teleflex's 2023 performance showed revenue growth and strong cash flow, with guidance for 2024 indicating continued growth and margin targets.
Despite challenges like declining EPS and recall impacts, the company aims for high EPS growth and sees opportunities in new markets and product expansions.
Confidence in meeting targets, pursuing strategic initiatives, and navigating market challenges position Teleflex for growth and profitability in the coming years.
Balancing financial performance with strategic investments and operational improvements will be key for Teleflex to capitalize on growth opportunities and overcome challenges.

Teleflex reports solid Q1 performance, eyes growth through acquisitions

Teleflex's Q1 2024 performance was solid, with revenue growth, margin expansion, and strong cash flow. Despite challenges like market multiples and recall impacts, the company is focused on growth opportunities and disciplined acquisitions to drive future success.

Teleflex reports solid Q2 growth, eyes M&A and product innovation

Teleflex's Q2 performance reflects steady growth, driven by strong results in key segments and product categories.
Despite challenges in certain areas, the company's strategic initiatives, including acquisitions and product innovation, position it well for future success.
With a focus on revenue growth, operational efficiency, and shareholder value, Teleflex is poised to capitalize on opportunities and navigate challenges effectively.

Teleflex reports solid Q3 earnings, eyes growth amid challenges

Teleflex's Q3 2024 performance showcased revenue growth, margin improvement, and strategic acquisitions driving increased revenue guidance for the year.
While facing challenges in specific product categories, the company's focus on innovation, market expansion, and financial strength positions it well for future growth.
Opportunities in expanding markets, disciplined capital allocation, and strong cash flow generation underscore Teleflex's resilience and potential for sustained success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Teleflex, Inc. provides medical technology products which enable healthcare providers to improve patient outcomes and enhance patient and provider safety. It operates through the following business segments: Americas, EMEA (Europe, the Middle East and Africa), Asia (Asia Pacific) and OEM. The Americas segment engages in the sales of interventional urology products. The EMEA engages in the sales of urology products. The Asia segment designs, manufactures and distributes medical devices primarily used in critical care, surgical applications and cardiac care and generally serves hospitals and healthcare providers. The OEM segment designs, manufactures and supplies devices and instruments for other medical device manufacturers. The company was founded in 1943 and is headquartered in Wayne, PA.

Product Pairing Offers an Impactful Partnership for Bariatric Surgery Product Pairing Offers an Impactful Partnership for Bariatric Surgery

Teleflex Selects GORE® SEAMGUARD® Bioabsorbable Staple Line Reinforcement Material for Use with Innovative Titan SGS® Stapler

Presentations at the 38th Annual European Association of Urology Congress Reinforce Low Surgical Retreatment of the UroLift® System

UroLift® System Research Data from EAU Highlight Durability and Superior Patient Experience, Along with Benefits of Earlier Treatment for BPH

WAYNE, Pa., March 07, 2023 (GLOBE NEWSWIRE) -- Thomas Powell, Executive Vice President and Chief Financial Officer, Teleflex Incorporated (NYSE: TFX), is scheduled to speak at the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum on Tuesday, March 21, 2023, at 12:00 p.m. (ET).

Teleflex to Present at the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum: Virtual

Teleflex (TFX) revenues in Asia rise backed by strong contributions from growth in all geographies.

Teleflex (TFX) Q4 Earnings Top Estimates, Operating Margin Down

Teleflex Incorporated (NYSE:TFX ) Q4 2022 Earnings Conference Call February 23, 2023 8:00 AM ET Company Participants Lawrence Keusch - Vice President, Investor Relations & Strategy Development Liam Kelly - Chairman, President & Chief Executive Officer Thomas Powell - Executive Vice President & Chief Financial Officer Conference Call Participants Cecilia Furlong - Morgan Stanley Mike Sarcone - Jefferies Shagun Singh - RBC Mike Polark - Wolfe Research Jayson Bedford - Raymond James Lawrence Biegelsen - Wells Fargo Michael Matson - Needham & Company Matthew O'Brien - Piper Sandler Anthony Petrone - Mizuho Craig Bijou - Bank of America Merrill Lynch George Sellers - Stephens Matt Mishan - KeyBanc Operator Good morning ladies and gentlemen and welcome to the Teleflex Fourth Quarter 2022 Earnings Conference Call. At this time, all participants have been placed in a listen-only mode.

Teleflex Incorporated (TFX) Q4 2022 Earnings Call Transcript

Teleflex (TFX) delivered earnings and revenue surprises of 2.33% and 0.31%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Teleflex (TFX) Surpasses Q4 Earnings Estimates

WAYNE, Pa., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) (the “Company”) today announced financial results for the fourth quarter ended December 31, 2022.

Teleflex Reports Fourth Quarter and Full Year 2022 Financial Results

Triumph™ Catheter and GuideLiner® Coast™ Catheter to be featured at the CTO Plus Conference, February 23-24 in New York, NY Triumph™ Catheter and GuideLiner® Coast™ Catheter to be featured at the CTO Plus Conference, February 23-24 in New York, NY

Teleflex Expands Interventional Cardiology Portfolio with Two New FDA-Cleared Catheter Devices for Use in Complex Percutaneous Coronary Interventions (PCI)

WAYNE, Pa., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Liam Kelly, Chairman, President and CEO, Teleflex Incorporated (NYSE: TFX), is scheduled to speak at the 44th Annual Raymond James Institutional Investors Conference at the JW Marriott Orlando Grande Lakes, Orlando, FL, on Tuesday, March 7, 2023, at 1:40 p.m. (ET).

Teleflex to Present at the 44th Annual Raymond James Institutional Investors Conference

WAYNE, Pa., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX) will host a conference call to discuss its fourth quarter financial results and provide an operational update at 8:00 a.m. Eastern Time on Thursday, February 23, 2023.

Teleflex Announces Fourth Quarter 2022 Earnings Conference Call Information

WAYNE, Pa., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced it was awarded a group purchasing organization (GPO) agreement with Premier®, Inc. for the Titan SGS® powered stapling device, expanding access to this innovative technology for surgeons affiliated with Premier.

Standard Bariatrics, Inc., now part of Teleflex, Awarded Bariatric Stapling Technology Agreement with Premier Inc.

The campaign drives education about the importance of regular health screenings and treatment options for benign prostatic hyperplasia (BPH), a common men's health condition. The campaign drives education about the importance of regular health screenings and treatment options for benign prostatic hyperplasia (BPH), a common men's health condition.

Teleflex Launches National Ad Campaign — “Pit Stop” — to Raise Awareness of the UroLift® System as a Treatment for Enlarged Prostate

NEW YORK--( BUSINESS WIRE )--Glancy Prongay & Murray LLP (“GPM”) announces its investigation of Teleflex Incorporated (NYSE: TFX) concerning the Company and its directors' and officers' possible violations of state laws.

Glancy Prongay & Murray LLP Announces Investigation of Teleflex Incorporated

Teleflex (TFX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Will Teleflex (TFX) Beat Estimates Again in Its Next Earnings Report?

Align Technology

Alnylam Pharmaceuticals

Baxter

BeiGene

Bristol-Myers

Royalty Pharma

Universal Health Services

Veeva Systems

Walgreens

Despite inflation making it hard for the healthcare industry to manage its operating costs, there are a few positives that make this sector attractive to investors.

5 Best and Worst Performing Health Care Stocks in December 2022

Investors are optimistic about Teleflex (TFX) on strong preference for the UroLift system.

Here's Why You Should Hold on to Teleflex (TFX) Stock for Now

From a geographic perspective, Teleflex (TFX) is seeing strong results in Asia, which continues to be an important growth driver for Teleflex.

Teleflex (TFX) OEM Arm Grows, Supply Issue Persists

WAYNE, Pa., Dec. 27, 2022 (GLOBE NEWSWIRE) -- Liam Kelly, Chairman, President and CEO, Teleflex Incorporated (NYSE: TFX), is scheduled to speak at the 41st Annual J.P. Morgan Healthcare Conference at The Westin St. Francis Hotel in San Francisco, California, on Tuesday, January 10, 2023, at 3:00 p.m. (PT).

Teleflex to Present at the 41st Annual J.P. Morgan Healthcare Conference

WAYNE, Pa., Dec. 15, 2022 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced that 400,000 patients have now been treated with the UroLift ® System,1 a safe, effective and minimally invasive treatment option for benign prostatic hyperplasia (BPH), or enlarged prostate.2 The UroLift ® System is the number one minimally invasive BPH procedure chosen by urologists and their patients in the U.S.3 The 5-year L.I.F.T. study results demonstrate UroLift® System durability with a surgical retreatment rate of about 2-3% per year and 13.6% total over 5 years.2

Teleflex Celebrates 400,000 Patients Treated With the Minimally Invasive UroLift® System

Teleflex stock (NYSE: TFX), best known for its single-use medical devices for common diagnostic and therapeutic procedures, has seen a 31% fall this year, underperforming the broader S&P500 index, down 16%.

Should You Buy Teleflex Stock At $225?

WAYNE, Pa., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today has announced it was named a MedReps.com 2023 Best Places to Work, earning the Number 1 spot for large companies and making this the sixth consecutive year the company has been on the list.

Teleflex Earns Top Spot in MedReps Best Places to Work 2023 Ranking

WAYNE, Pa., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Liam Kelly, Chairman, President and CEO, Teleflex Incorporated (NYSE: TFX), is scheduled to speak at the 34th Annual Piper Sandler Healthcare Conference at The Lotte New York Palace, New York, NY, on Wednesday, November 30, 2022 at 1:30 p.m. (ET).

Teleflex to Present at the 34th Annual Piper Sandler Healthcare Conference

WAYNE, Pa., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies for critical care and surgery, has announced a worldwide recall of affected lots of the below-referenced Gibeck® Iso-Gard® Filter products. The Gibeck® Iso-Gard® Filter is a bacterial and viral filter, intended for connection to respiratory equipment in intensive care units and operating theatres to protect the equipment from potential airborne contaminants.

Teleflex Announces Worldwide Recall of Gibeck® Iso-Gard® Filter

U.S. health regulators on Tuesday classified the recall of Teleflex Inc's Iso-Gard filter S, a medical device to protect patients from potential airborne contaminants, as most serious, saying its use could lead to injuries or death.

U.S. FDA classifies recall of Teleflex's respiratory filters as most serious

For UroLift, Teleflex (TFX) currently assumes 2022 revenues to be roughly $320 million, down from the prior guidance of $335 million.

News for Teleflex Stock (TFX)